Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.56 |
| ▸ | HTR1D | P28221 | 4/20 | 0.56 |
| ▸ | HTR1B | P28222 | 4/20 | 0.56 |
| ▸ | HTR1F | P30939 | 3/20 | 0.56 |
| ▸ | HTR7 | P34969 | 3/20 | 0.56 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HTR1E | P28566 | 2/20 | 0.56 |
| ▸ | HTR2B | P41595 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | HTR3A | P46098 | 1/20 | 0.56 |
| ▸ | HTR5A | P47898 | 1/20 | 0.56 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.56 |
| ▸ | HTR6 | P50406 | 17/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9688466 | 0.85 | HTR1A (0.60) | HTR1AHTR1DHTR1BHTR1FHTR7 | |
| SCHEMBL9687324 | 0.83 | HTR1A (0.57) | HTR1AHTR1DHTR1BHTR1FHTR7 | |
| SCHEMBL13651695 | 0.82 | HTR1A (0.56) | HTR1AHTR1DHTR1BHTR1FHTR7 | |
| Hydrochloric Acid SCHEMBL9687692 | 0.82 | HTR1A (0.56) | HTR1AHTR1DHTR1BHTR1FHTR7 | |
| SCHEMBL10108909 | 0.82 | HTR1A (0.60) | HTR1AHTR1DHTR1BHTR1FHTR7 | |
| SCHEMBL9597932 | 0.81 | HTR1A (0.55) | HTR1AHTR1DHTR1BHTR1FHTR7 | |
| SCHEMBL9687900 | 0.81 | HTR1A (0.55) | HTR1AHTR1DHTR1BHTR1FHTR7 | |
| SCHEMBL9597530 | 0.80 | HTR1A (0.53) | HTR1AHTR1DHTR1BHTR1FHTR7 | |
| SCHEMBL9765127 | 0.80 | HTR6 (0.61) | HTR1AHTR1DHTR1BHTR1FHTR7 | |
| Oxalic Acid SCHEMBL9597338 | 0.77 | HTR1A (0.51) | HTR1AHTR1DHTR1BHTR1FHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261950-A1 | Compounds that inhibit cholinesterase | ACHE, BCHE, CHAT | HTR1A 1027/4885HTR1D 1726/4885HTR1B 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.